- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Peter Jørgensen: The Impact of Biosimilars on Danish Patients
Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Danish patients are benefitting from biosimilars.
Transcript
I think the Danish patients are being impacted in several ways. Firstly, more patients have now access to biological treatment than what they did before; as we all know, biologic medicines have been very, very expensive. They have also been very efficient, but they have been very expensive in Denmark. Last year, of 25 products being used in Danish hospitals, 24 of them were biologics. Of course they have been expensive, but now when you add biosimilars into the market, more patients are being treated, and they're being treated earlier.
At the same time, this would also free up money in other places of the system. We all know we are having a lot of new cancer products coming in. They are, I assume, efficient, but for certain, very expensive.
The fact that you can save a lot of money by using biosimilars will, as I say, free up money that means that other patients, cancer patients, for instance, can benefit because you can start to use new treatment at an earlier point in time without jeopardizing the total health care budget.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
